Medicine & Life Sciences
Hodgkin Disease
100%
Brentuximab Vedotin
68%
Rituximab
55%
Lymphoma, Large B-Cell, Diffuse
46%
Non-Hodgkin's Lymphoma
44%
Follicular Lymphoma
37%
Progression-Free Survival
35%
Lymphoma
32%
B-Cell Lymphoma
31%
Drug Therapy
25%
PCI 32765
24%
Survival
24%
Lenalidomide
22%
Doxorubicin
22%
Therapeutics
20%
Bendamustine Hydrochloride
20%
Mantle-Cell Lymphoma
18%
B-Cell Chronic Lymphocytic Leukemia
16%
Chimeric Antigen Receptors
15%
ibritumomab tiuxetan
14%
Safety
14%
Positron-Emission Tomography
13%
axicabtagene ciloleucel
13%
Cyclophosphamide
13%
Vincristine
12%
Anaplastic Large-Cell Lymphoma
12%
Peripheral T-Cell Lymphoma
12%
Radioimmunotherapy
12%
Prednisone
12%
Neoplasms
12%
Transplants
11%
Radiotherapy
11%
Clinical Trials
11%
T-Lymphocytes
10%
Stem Cell Transplantation
10%
Vinblastine
9%
Multicenter Studies
9%
Neutropenia
9%
Etoposide
9%
Leukemia
9%
Immunotherapy
8%
Immunoconjugates
8%
Thrombocytopenia
8%
Dacarbazine
8%
gemcitabine
8%
Bortezomib
8%
Bleomycin
8%
Nivolumab
8%
dacetuzumab
7%
Confidence Intervals
7%